Drug Profile


Alternative Names: Glycopeptide-cephalosporin heterodimer (TD-1792); Heterodimer antibacterial - Theravance Biopharma; TD-1792

Latest Information Update: 18 Jan 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline; Theravance
  • Developer Theravance Biopharma
  • Class Acetamides; Antibacterials; Azabicyclo compounds; Beta-lactams; Cephalosporins; Peptide antibiotics; Pyridines; Thiazoles
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gram-positive infections; Skin and soft tissue infections

Most Recent Events

  • 18 Jan 2016 Phase-III clinical trials in Gram-positive infections and Skin and soft tissue infections in USA prior to January 2016 (IV) (Theravance Biopharma pipeline, January 2016)
  • 17 Jun 2015 Phase II development is ongoing the USA
  • 02 Jun 2014 Theravance Biopharma is formed as a spin-off of Theravance
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top